drug_type
RELEVANT_DRUG
intervention_type
Therapeutic cancer vaccine (peptide vaccine)
drug_description
Subcutaneous long-peptide therapeutic cancer vaccine targeting PD-L1, designed to elicit PD-L1–specific CD4+ and CD8+ T cells to attack PD-L1–expressing tumor and immunosuppressive cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_category
PEPTIDE VACCINE
drug_class
Vaccine
drug_delivery_route
Subcutaneous
drug_mechanism_of_action
Subcutaneous long-peptide cancer vaccine composed of PD-L1–derived peptides that prime and expand PD-L1–specific CD4+ helper and CD8+ cytotoxic T cells. The induced T cells recognize PD-L1–expressing tumor and immunosuppressive cells and eliminate them, reducing immune suppression and enhancing antitumor immunity. It does not block PD-1/PD-L1 directly like an antibody checkpoint inhibitor.
drug_name
IO103
nct_id_drug_ref
NCT05912244